A postoperative tumor-specific death prediction model for patients with endometrial cancer: a retrospective study
Original Article

A postoperative tumor-specific death prediction model for patients with endometrial cancer: a retrospective study

Hailong Chen1#, Weiwei Yan2#, Dechang Xu1, Qi Wang1, Ying Yu1, Jing Huang1, Qian Zhou3, Wei Xiao1, David Lukanovic4, Fabio Barra5,6, Alberto Izzotti7,8, Feizhou Jiang9

1Department of Gynecomatology, Ganzhou Cancer Hospital, Ganzhou, China; 2Department of Obstetrics and Gynecology, The First People’s Hospital of Jiangxia District Wuhan City, Wuhan, China; 3Department of Vascular Hernia Surgery, Ganzhou People’s Hospital, Ganzhou, China; 4Division of Gynecology and Obstetrics, Ljubljana University Medical Center, Ljubljana, Slovenia; 5Unit of Obstetrics and Gynecology, P.O. “Ospedale del Tigullio”-ASL4, Metropolitan Area of Genoa, Genoa, Italy; 6Department of Health Sciences (DISSAL), University of Genoa, Genoa, Italy; 7Unit of Mutagenesis and Cancer Prevention, IRCCS Ospedale Policlinico San Martino, Genoa, Italy; 8Department of Experimental Medicine (DIMES), University of Genoa, Genoa, Italy; 9Department of Obstetrics and Gynecology, Dushu Lake Hospital Affiliated to Soochow University, Suzhou, China

Contributions: (I) Conception and design: H Chen, W Yan; (II) Administrative support: F Jiang; (III) Provision of study materials or patients: All authors; (IV) Collection and assembly of data: All authors; (V) Data analysis and interpretation: All authors; (VI) Manuscript writing: All authors; (VII) Final approval of manuscript: All authors.

#These authors contributed equally to this work.

Correspondence to: Feizhou Jiang, MD, PhD. Department of Obstetrics and Gynecology, Dushu Lake Hospital Affiliated to Soochow University, No. 9 Chongwen Road, Suzhou Industrial Park, Suzhou 215100, China. Email: fzjiang@suda.edu.cn.

Background: Endometrial cancer (EC) is an epithelial malignancy occurring in the endometrium, with a 5-year mortality rate of above 10%. However, there is currently a lack of studies exploring the potential of a predictive model of tumor-specific death after surgery in these patients.

Methods: From January 2015 to December 2017, data related to 482 patients with EC admitted to the Dushu Lake Hospital Affiliated to Soochow University were analyzed. Patients were divided into death (n=62) and survival (n=420) groups according to whether tumor-specific death occurred at 5 years postoperatively or not. The clinical characteristics of the two groups were compared, and the risk factors for tumor-specific death in patients with EC 5 years after surgery were investigated by logistics regression analysis. A nomogram prediction model was established according to the relevant risk factors.

Results: Tumor size, Ki-67 positive rate, Federation International of Gynecology and Obstetrics (FIGO) stage, and the rate of vascular tumor thrombus between the two groups (P<0.05) were found to be the statistically significant factors. Positive Ki-67, tumor size >3.35 cm, stage III, and vascular tumor thrombus were factors that influenced the tumor-specific death at 5 years after surgery (P<0.05). The predictive model obtained an area under the receiver operating characteristic (ROC) curves in the training and verification sets of 0.847 [95% confidence interval (CI): 0.779–0.916] and 0.886 (95% CI: 0.803–0.969), respectively.

Conclusions: The nomogram prediction model, which was established in this study, was proved to be valuable in predicting tumor-specific death 5 years after the surgery in patients with EC.

Keywords: Endometrial cancer (EC); predictive models; nomogram; tumor-specific death

Submitted Oct 22, 2023. Accepted for publication Dec 01, 2023. Published online Feb 02, 2024.

doi: 10.21037/tcr-23-1959

Highlight box

Key findings

• The nomogram prediction model, which was established in this study, was proved to be valuable in predicting tumor-specific death 5 years after the surgery in patients with endometrial cancer (EC).

What is known and what is new?

• EC is an epithelial malignancy occurring in the endometrium, with a 5-year mortality rate of above 10%.

• A nomogram prediction model for EC tumor-specific death was established in this study.

What is the implication, and what should change now?

• Identifying the high risk group of tumor-specific death in patients with EC with this model may be beneficial for improving the prognosis by strengthening the management of this population.

Introduction

Endometrial cancer (EC) is a type of epithelial malignancy that occurs in the endometrium, with a 5-year tumor-specific mortality rate of 10–30% (1-3). Accurately identifying the high risk EC patients who are likely to experience tumor-specific death within 5 years after surgery can provide a solid theoretical basis for implementing effective management strategies for such patients. Risk factors for poor prognosis in patients with EC have been explored, and the study from Brasky et al. showed that the use of non-steroidal anti-inflammatory drugs (NSAIDs) is associated with higher mortality (1). Tubal ligation has also been found to be associated with a poor prognosis of patients with EC (2).

A previous study showed that age, ethnicity, marital status, Federation International of Gynecology and Obstetrics (FIGO) stage are independent factors influencing the prognosis of patients with EC. A predictive model was also established based on the relevant risk factors, which showed good accuracy in assessing the prognosis of patients with EC (3). Another study involving patients with type II EC (endometrial serous papillary adenocarcinoma) showed that age, marital status, tumor size, tumor node metastasis (TNM) stage, surgery, radiotherapy, and chemotherapy are independent factors affecting prognosis (4).

However, in clinical practice, more attention is given to the prognosis of patients with early- and intermediate-stage EC who receive surgical treatment. Thus, it is necessary to explore the risk factors for tumor-specific death in patients with EC at 5 years postoperatively. In the present study, we aimed to identify the risk factors of tumor-specific death after surgery and to establish and validate a postoperative tumor-specific death prediction model for patients with EC. We present this article in accordance with the TRIPOD reporting checklist (available at https://tcr.amegroups.com/article/view/10.21037/tcr-23-1959/rc).

Methods

General information

From January 2015 to December 2017, clinical data of 482 patients with EC, who were admitted to the Dushu Lake Hospital Affiliated to Soochow University, were analyzed. The patients were divided into death (n=62) and survival (n=420) groups according to whether tumor-related death occurred within 5 years postoperatively. The inclusion criteria were as follows: (I) diagnosis of EC (based on postoperative biopsy); (II) age ≥18 years old; (III) surgical treatment performed at the Dushu Lake Hospital Affiliated to Soochow University; (IV) stage of the FIGO: I–III; and (V) availability of complete clinical data. Patients were excluded based on the following criteria: (I) concomitant presence of other malignant tumors, such as gastric cancer; (II) perioperative death; and (III) lost to follow-up. This retrospective clinical study was performed in accordance with the Declaration of Helsinki (as revised in 2013). The study was approved by the ethics committee of Dushu Lake Hospital Affiliated to Soochow University (No. 20200048) and was exempt from the requirement to obtain informed consent due to the retrospective nature of this study.

Treatment

According to the treatment guidelines for EC (5), all patients received an accurate preoperative examination after admission and underwent surgical treatment. Pelvic and paraaortic nodes, bilateral salpingo-oophorectomy and retroperitoneal lymph node resection were performed when it was deemed necessary. Adjuvant therapy, such as radiotherapy and chemotherapy, was decided according to the pathological results after surgery. Postoperative follow-up was conducted through outpatient visits and, eventually, by telephone.

Data collection

Patient data including age, body mass index (BMI), marital status, history of smoking, history of alcoholism, hypertension, diabetes, hyperlipidemia, carbohydrate antigen 125 (CA125), Ki-67 (the standard of positive Ki-67: Ki-67 >20%), tumor size, FIGO stage (2018 version), EC type, tumor cell differentiation, vascular tumor thrombus (vascular tumor thrombus: malignant tumor cells invaded the blood vessels or lymphatic vessels, resulting in tumor thrombus that representing poor prognosis), postoperative radiotherapy, postoperative chemotherapy and postoperative 5-year tumor-specific mortality were collected.

Statistical analysis

SPSS26.0 (IBM, Chicago, IL, USA) was used to complete the data analysis, and P<0.05 indicated that differences were statistically significant (two-tailed). The measurement data of the two groups were expressed by the mean ± standard deviation, and an independent sample t-test was used to analyze the differences. The count data of the two groups were expressed by n (%), and the Chi-squared test was used to analyze the differences. The risk factors of tumor-specific death were studied using the multivariate logistics regression analysis. The receiver operating characteristic (ROC) curve was used to study the predictive value of different indexes on tumor-specific death. R4.0.3 statistical software (R Development Core Team) was used to construct the prediction model.

Results

Comparison of the clinical features between the two groups

The flow chart of EC patient inclusion in this study is shown in Figure 1. Statistically significant differences were found in tumor size, positive Ki-67 rate, FIGO stage, and the rate of vascular tumor thrombus between the two groups (P<0.05) (see Table 1).

Figure 1 Flow chart of inclusion in this study.

Table 1

Comparison of the clinical features between the two groups

Variables Death group (n=62) Survival group (n=420) t/χ2 value P value
Age (years) 60.89±10.48 59.98±11.66 0.581 0.561
Body mass index (kg/m2) 25.05±3.48 24.45±3.33 1.335 0.183
Marital status 1.733 0.630
   Unmarried 1 (1.61) 9 (2.14)
   Married 43 (69.35) 288 (68.57)
   Divorce 12 (19.35) 62 (14.76)
   Widowed 6 (9.68) 61 (14.52)
History of smoking 8 (12.90) 50 (11.90) 0.051 0.822
History of alcoholism 4 (6.45) 35 (8.33) 0.257 0.612
Hypertension 10 (16.13) 62 (14.76) 0.079 0.778
Diabetes 5 (8.06) 30 (7.14) 0.068 0.794
Hyperlipidemia 16 (25.81) 102 (24.29) 0.068 0.795
CA125 (IU/L) 22.34±13.27 21.80±13.26 0.296 0.767
Positive Ki-67 12.782 <0.001
   Yes 37 (59.68) 151 (35.95)
   No 25 (40.32) 269 (64.05)
Tumor size (cm) 4.01±1.05 2.85±1.21 7.121 <0.001
Tumor size >3.35 cm 43 (69.35) 159 (37.86) 22.016 <0.001
FIGO stage 56.612 <0.001
   Stage I or II 41 (66.13) 399 (95.00)
   Stage III 21 (33.87) 21 (5.00)
Endometrial cancer type 0.013 0.910
   I type 32 (51.61) 220 (52.38)
   II type 30 (48.39) 200 (47.62)
Tumor cell differentiation 2.202 0.138
   Low 21 (33.87) 105 (25.00)
   Medium to high 41 (66.13) 315 (25.00)
Vascular tumor thrombus 52.422 <0.001
   Yes 18 (29.03) 16 (3.81)
   No 44 (70.97) 404 (96.19)
Postoperative radiotherapy 54 (87.10) 312 (74.29) 2.662 0.103
Postoperative chemotherapy 29 (46.77) 154 (36.67) 2.343 0.126

Data are shown as mean ± standard deviation or n (%). CA125, carbohydrate antigen 125; FIGO, Federation International of Gynecology and Obstetrics.

The value of tumor size in predicting tumor-specific death 5 years after surgery in patients with EC.

Tumor size was valuable for predicting tumor-specific death with an area under the curve (AUC) of 0.754 [95% confidence interval (CI): 0.696–0.812, P<0.001]. The optimal diagnostic cut-off was 3.35 cm, for which the sensitivity and specificity were 0.694 and 0.621, respectively (see Figure 2).

Figure 2 The value of tumor size in predicting the tumor-specific death at 5 years after surgery.

Risk factors of tumor-specific death 5 years after surgery.

The presence of immunohistochemical positivity of Ki-67, a tumor size >3.35 cm, FIGO stage III disease, and vascular tumor thrombus were factors that influenced the tumor-specific death (P<0.05) (see Table 2).

Table 2

Risk factors of tumor-specific death at 5 years after surgery

Variables B value Standard error Wald value P value Relative risk (95% CI)
Positive Ki-67 0.690 0.324 4.550 0.033 1.994 (1.058–3.760)
Tumor size >3.35 cm 1.381 0.339 16.612 <0.001 3.979 (2.048–7.731)
Stage III 2.473 0.400 38.137 <0.001 11.857 (5.409–23.992)
Vascular tumor thrombus 2.706 0.440 37.787 <0.001 14.966 (6.316–35.465)
Constant −10.743 1.435 56.079 <0.001 0.000

CI, confidence interval.

Establishment and validation of a tumor-specific death prediction model for patients with EC 5 years after surgery.

The dataset of patients was randomly divided into training and validation sets, consisting of 337 and 145 samples, respectively. According to the risk factors mentioned above, the nomogram prediction model was constructed. The AUCs of the ROC curve of the training and validation sets were 0.847 (95% CI: 0.779–0.916) and 0.886 (95% CI: 0.803–0.969), respectively. In the validation set, the model was tested with Hosmer-Lemeshow Goodness-of-Fit achieving a Chi-squared value of 5.711 and a P value of 0.680 (see Figures 3-6).

Figure 3 Nomogram of a tumor-specific death prediction model at 5 years after surgery. FIGO, Federation International of Gynecology and Obstetrics.
Figure 4 Calibration curve of the tumor-specific death prediction model.
Figure 5 Predictive value of the predictive model for tumor-specific death at 5 years after surgery (the top figure was the training set; the bottom figure was the validation set). AUC, area under the curve.
Figure 6 Clinical decision curve of the tumor-specific death prediction model.

Discussion

In the present study, we found that positive Ki-67, tumor size >3.35 cm, stage III, and vascular tumor thrombus were factors that influenced the tumor-specific death (P<0.05). Ki-67 is a proliferating cell-related antigen that is closely related to mitosis and cell proliferation. Therefore, Ki67 is mainly used to label cells in the proliferation cycle, and a higher Ki-67 positive rate indicates more rapid tumor growth, signifying worse tissue differentiation and poor prognosis (6). Previous studies in patients with EC have confirmed that high Ki-67 expression is a risk factor for poor prognosis, which is consistent with the findings of the present study (6-9). Studies have also shown that tumor diameter is related to deep muscular invasion, lymph node metastasis, and lymphovascular space invasion, suggesting that increased tumor diameter represents also a factor leading to poor prognosis (10-12). The FIGO stage is a more widely used and authoritative staging system; according to stage III of the disease, the tumor has invaded the uterine serosal layer or fallopian tubes. For these patients, the rate of postoperative recurrence and distant metastasis is high, even with aggressive surgical treatment, ultimately worsening the patient’s prognosis (13,14). When the tumor thrombus enters the blood or lymphatic vessels, vascular tumor thrombus may lead to lymph node metastasis and, also, distant metastasis (15,16). In pathology, a vascular tumor thrombus is used as an important biological indicator to evaluate the degree of malignancy and is an important marker of recurrence and prognosis. Moreover, studies have confirmed that it is also a risk factor for lymph node metastasis (17,18).

At the same time, we also established a nomogram prediction model to more intuitively identify the high risk group of tumor-specific death in patients with EC 5 years after surgery and found that the predictive model was reliable. Nomogram predictive models can accurately identify the high risk group of poor prognosis in a variety of diseases (13,19-22). Some authors have discussed on the role of nomogram predictive models in evaluating patients with EC and found that predictive models have good evaluation value (3,4). The present study differed from the previous studies by focusing on EC patients who received surgical treatment. The management model, such as surgery and radiochemotherapy, for patients in the present study was more unified. Exploring the prognosis of various diseases is the focus of current research (23-26), therefore, the present study is valuable.

Limitations and strengths of the study

The limitations of this study included the fact that this was a retrospective clinical study with a relatively small number of events (deaths). Previous studies have confirmed that the Radiomics and Molecular Classification were associated with the prognosis (27,28). However, due to the limitations of the retrospective study, some indicators such as Radiomics and Molecular Classification were not included in the present study. The strengths of this study included that the nomogram prediction model established in the present study was valuable in its capability to accurately predict tumor-specific death and its differences with previous studies.

Conclusions

The nomogram prediction model established in the present study is valuable in its capability to accurately predict tumor-specific death. Identifying the high risk group of tumor-specific death with this model may be beneficial for improving patient outcomes by strengthening the management of this population; however, further clinical studies are needed.

Acknowledgments

Funding: None.

Footnote

Reporting Checklist: The authors have completed the TRIPOD reporting checklist. Available at https://tcr.amegroups.com/article/view/10.21037/tcr-23-1959/rc

Data Sharing Statement: Available at https://tcr.amegroups.com/article/view/10.21037/tcr-23-1959/dss

Peer Review File: Available at https://tcr.amegroups.com/article/view/10.21037/tcr-23-1959/prf

Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://tcr.amegroups.com/article/view/10.21037/tcr-23-1959/coif). The authors have no conflicts of interest to declare.

Ethical Statement: The authors are accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. This retrospective clinical study was performed in accordance with the Declaration of Helsinki (as revised in 2013). The study was approved by the ethics committee of Dushu Lake Hospital Affiliated to Soochow University (No. 20200048) and was exempt from the requirement to obtain informed consent due to the retrospective nature of this study.

Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0/.

References

  1. Brasky TM, Felix AS, Cohn DE, et al. Nonsteroidal Anti-inflammatory Drugs and Endometrial Carcinoma Mortality and Recurrence. J Natl Cancer Inst 2017;109:1-10. [Crossref] [PubMed]
  2. Felix AS, Brinton LA, McMeekin DS, et al. Relationships of Tubal Ligation to Endometrial Carcinoma Stage and Mortality in the NRG Oncology/ Gynecologic Oncology Group 210 Trial. J Natl Cancer Inst 2015;107:djv158. [Crossref] [PubMed]
  3. Li R, Yue Q. A nomogram for predicting overall survival in patients with endometrial carcinoma: A SEER-based study. Int J Gynaecol Obstet 2023;161:744-50. [Crossref] [PubMed]
  4. Ren X, Wang MM, Wang G, et al. A nomogram for predicting overall survival in patients with type II endometrial carcinoma: a retrospective analysis and multicenter validation study. Eur Rev Med Pharmacol Sci 2023;27:233-47. [PubMed]
  5. Concin N, Matias-Guiu X, Vergote I, et al. ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma. Radiother Oncol 2021;154:327-53. [Crossref] [PubMed]
  6. Jiang X, Jia H, Zhang Z, et al. The Feasibility of Combining ADC Value With Texture Analysis of T(2)WI, DWI and CE-T(1)WI to Preoperatively Predict the Expression Levels of Ki-67 and p53 of Endometrial Carcinoma. Front Oncol 2022;11:805545. [Crossref] [PubMed]
  7. Li Y, Lin CY, Qi YF, et al. Three-dimensional turbo-spin-echo amide proton transfer-weighted and intravoxel incoherent motion MR imaging for type I endometrial carcinoma: Correlation with Ki-67 proliferation status. Magn Reson Imaging 2021;78:18-24. [Crossref] [PubMed]
  8. Jiang JX, Zhao JL, Zhang Q, et al. Endometrial carcinoma: diffusion-weighted imaging diagnostic accuracy and correlation with Ki-67 expression. Clin Radiol 2018;73:413.e1-6. [Crossref] [PubMed]
  9. Yu CG, Jiang XY, Li B, et al. Expression of ER, PR, C-erbB-2 and Ki-67 in Endometrial Carcinoma and their Relationships with the Clinicopathological Features. Asian Pac J Cancer Prev 2015;16:6789-94. [Crossref] [PubMed]
  10. Ali M, Mumtaz M, Naqvi Z, et al. Assessing Tumor Size by MRI and Pathology in Type I Endometrial Carcinoma to Predict Lymph Node Metastasis. Cureus 2022;14:e23135. [Crossref] [PubMed]
  11. Oliver-Perez MR, Magriña J, Villalain-Gonzalez C, et al. Lymphovascular space invasion in endometrial carcinoma: Tumor size and location matter. Surg Oncol 2021;37:101541. [Crossref] [PubMed]
  12. Nakamura K, Nakayama K, Ishikawa N, et al. Preoperative tumor size is associated with deep myometrial invasion and lymph node metastases and is a negative prognostic indicator for patients with endometrial carcinoma. Oncotarget 2018;9:23164-72. [Crossref] [PubMed]
  13. Zhao M, Wen F, Shi J, et al. MRI-based radiomics nomogram for the preoperative prediction of deep myometrial invasion of FIGO stage I endometrial carcinoma. Med Phys 2022;49:6505-16. [Crossref] [PubMed]
  14. Wang Y, Zhang C. Aberrant TRPC1 expression reflects stromal cervical invasion, lymphovascular invasion, elevated FIGO stage, and poor survival in resectable endometrial carcinoma patients. J Clin Lab Anal 2022;36:e24560. [Crossref] [PubMed]
  15. Song Y, Chen D, Lian D, et al. Study on the Correlation Between CT Features and Vascular Tumor Thrombus Together With Nerve Invasion in Surgically Resected Lung Adenocarcinoma. Front Surg 2022;9:931568. [Crossref] [PubMed]
  16. Caño Velasco J, Polanco Pujol L, Herranz Amo F, et al. Utility of preoperative vascular embolization of renal tumors with left renal vein tumor thrombus. Actas Urol Esp 2021;45:615-22. (Engl Ed). [Crossref] [PubMed]
  17. Kasai Y, Hatano E, Seo S, et al. Hepatocellular carcinoma with bile duct tumor thrombus: surgical outcomes and the prognostic impact of concomitant major vascular invasion. World J Surg 2015;39:1485-93. [Crossref] [PubMed]
  18. Yuan W, Li F. Roles of microRNA-186 and vascular endothelial growth factor in hepatocellular carcinoma complicated with portal vein tumor thrombus. Exp Ther Med 2020;20:3860-7. [Crossref] [PubMed]
  19. Yuan Y, Wang R, Zhang Y, et al. A new nomogram for predicting lung metastasis in newly diagnosed endometrial carcinoma patients: A study based on SEER. Front Surg 2022;9:855314. [Crossref] [PubMed]
  20. Long L, Sun J, Jiang L, et al. MRI-based traditional radiomics and computer-vision nomogram for predicting lymphovascular space invasion in endometrial carcinoma. Diagn Interv Imaging 2021;102:455-62. [Crossref] [PubMed]
  21. Tong H, Feng H, Hu X, et al. Identification of Interleukin-9 Producing Immune Cells in Endometrial Carcinoma and Establishment of a Prognostic Nomogram. Front Immunol 2020;11:544248. [Crossref] [PubMed]
  22. Luo Y, Mei D, Gong J, et al. Multiparametric MRI-Based Radiomics Nomogram for Predicting Lymphovascular Space Invasion in Endometrial Carcinoma. J Magn Reson Imaging 2020;52:1257-62. [Crossref] [PubMed]
  23. Chen Y, Wang J, Zhang X, et al. Correlation between apparent diffusion coefficient and pathological characteristics of patients with invasive breast cancer. Ann Transl Med 2021;9:143. [Crossref] [PubMed]
  24. Qi A, Li Y, Yan S, et al. Effect of postoperative chemotherapy on blood glucose and lipid metabolism in patients with invasive breast cancer. Gland Surg 2021;10:1470-7. [Crossref] [PubMed]
  25. He XC, Chen HY, Qiu Y, et al. Associations of iron status with breast cancer risk factors in adult women: Findings from National Health and Nutrition Examination Survey 2017-2018. J Trace Elem Med Biol 2021;68:126867. [Crossref] [PubMed]
  26. Teng D, Xia S, Hu S, et al. miR-887-3p Inhibits the Progression of Colorectal Cancer via Downregulating DNMT1 Expression and Regulating P53 Expression. Comput Intell Neurosci 2022;2022:7179733. [Crossref] [PubMed]
  27. Di Donato V, Kontopantelis E, Cuccu I, et al. Magnetic resonance imaging-radiomics in endometrial cancer: a systematic review and meta-analysis. Int J Gynecol Cancer 2023;33:1070-6. [Crossref] [PubMed]
  28. Bogani G, Chiappa V, Lopez S, et al. Radiomics and Molecular Classification in Endometrial Cancer (The ROME Study): A Step Forward to a Simplified Precision Medicine. Healthcare (Basel) 2022;10:2464. [Crossref] [PubMed]
Cite this article as: Chen H, Yan W, Xu D, Wang Q, Yu Y, Huang J, Zhou Q, Xiao W, Lukanovic D, Barra F, Izzotti A, Jiang F. A postoperative tumor-specific death prediction model for patients with endometrial cancer: a retrospective study. Transl Cancer Res 2024;13(2):1083-1090. doi: 10.21037/tcr-23-1959

Article Options

Download Citation

Share